3

Chromos Molecular Systems Inc. (CHR-T Unlisted)

ON STOCKCHASE SINCE Nov 2004

Make artificial chromosones.

biotechnology/pharmaceutical

Chromos Molecular Systems...
CHR-T Unlisted

12 watching

Join the Discussion

Expert Opinions
0 comments
Your Reaction

0 0 0 0 0

What the experts are saying about CHR-T Unlisted

Signal	Opinion	Expert
BUY	Chromos Molecular Systems Inc.(CHR-T Unlisted) August 16, 2016 Likes the story. They’ve switched their contract and he feels the company came out very well in the negotiations. They moved from a spread over costs which Air Canada (AC-T) used to pay, to a fixed price contract, which is very good for this company. Over the duration of the 10 years that the contract was reset for, the dividend is sustainable. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Likes the story. They’ve switched their contract and he feels the company came out very well in the negotiations. They moved from a spread over costs which Air Canada (AC-T) used to pay, to a fixed price contract, which is very good for this company. Over the duration of the 10 years that the contract was reset for, the dividend is sustainable. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Andrew Pink Portfolio , LDIC... Price $0.040 Owned Yes

BUY	Chromos Molecular Systems Inc.(CHR-T Unlisted) July 13, 2016 (Market Call Minute) They love it. The company is not responsible for any of the variable costs. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(Market Call Minute) They love it. The company is not responsible for any of the variable costs. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Bruce Murray CEO & Chie, The Murray Wealth Gr... Price $0.040 Owned Unknown
HOLD	Chromos Molecular Systems Inc.(CHR-T Unlisted) November 12, 2004 Good technology which should win Nobel prizes 5/10 years. Running out of cash. The big question is; will they survive. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Good technology which should win Nobel prizes 5/10 years. Running out of cash. The big question is; will they survive. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Duncan Stewart Director o, DSAM Consulting... Price $0.570 Owned Yes

4+

JOIN THE DISCUSSION
4 comments in the last 7 days

Stockchase, in its reporting on what has been discussed by indviduals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc. & Wealthica Financial Technology Inc.